In Brief: J&J Snags NeoStrata; FDA Sets ICCR Prep; IRI Names Pacesetters
This article was originally published in The Rose Sheet
Executive Summary
Johnson & Johnson says its acquisition of NeoStrata will complement its existing skin-care portfolio. Meanwhile, FDA seeks public input at a meeting in advance of the upcoming International Cooperation on Cosmetics Regulation. More news in brief.